1. 2023PEvaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx. (1st October 2019) Authors: Ota, K; Ueno, T; Nakanishi, T; Nakano, T; Yamashita, T; Yoshimi, M; Fujita, A; Okabayashi, H; Tao, Y; Takata, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 528PThe impact of continuing ALK inhibitors beyond initial disease progression on clinical outcome in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter retrospective analysis. (25th November 2018) Authors: Sakata, S; Saeki, S; Sakata, Y; Kawamura, K; Ichikado, K; Inaba, M; Ushijima, S; Imamura, K; Iyonaga, K; Kumabe, T; Fujita, R; Kashiwabara, K; Fujii, S; Komatsu, T; Sakamoto, O; Okabayashi, H; Saruwatari, K; Tomita, Y; Sakagami, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗